

Lab Report from LabCorp

Specimen Number		Patient ID		Control Number		Account Number	
14447708100		110814191		3221837		04099960	
Patient Last Name				Account Address			
ENRIQUEZ				One Medical Group 10000 W Washington Blvd Suite 108 Culver City CA 90232			
Patient First Name		Patient Middle Name					
LAURA							
Patient SS#	Patient Phone	Total Volume					
	323-253-5907						
Date of Birth		Sex	Fasting		Additional Information		
1989-10-09		F	N				
Patient Address							
5729 CLEMSON ST LOS ANGELES CA, 90016-0000				Physician Name			
Date/Time Collected		Date Entered		Date/Time Reported		NPI #	
2021-05-24 05:43:00 PDT		2021-05-24 21:00:00 PDT		2021-05-27 21:05:00 PDT		1821587890	
				BHATIA, T		Physician ID	

Tests Ordered

CBC With Differential/Platelet (005009); Comp. Metabolic Panel (14) (322000); Lipid Panel (303756); ANA (340897); Hemoglobin A1c (001453); Thyroxine (T4) Free, Direct, S (001974); TSH (004259); Vitamin D, 25-Hydroxy (081950); CCP Antibodies IgG/IgA (164914); Rheumatoid Arthritis Factor (006502); Sedimentation Rate-Westergren (005215); Triiodothyronine (T3), Free (010389); C-Reactive Protein, Quant (006627)

TESTS	RESULTS	FLAG	UNITS	REFERENCE INTERVAL	LAB
CBC With Differential/Platelet					
WBC	6.5		x10E3/uL	3.4-10.8	01
RBC	4.55		x10E6/uL	3.77-5.28	01
Hemoglobin	13.5		g/dL	11.1-15.9	01
Hematocrit	39.9		%	34.0-46.6	01
MCV	88		fL	79-97	01
MCH	29.7		pg	26.6-33.0	01
MCHC	33.8		g/dL	31.5-35.7	01
RDW	13.0		%	11.7-15.4	01
Platelets	260		x10E3/uL	150-450	01
Neutrophils	58		%	Not Estab.	01
Lymphs	27		%	Not Estab.	01
Monocytes	8		%	Not Estab.	01
Eos	6		%	Not Estab.	01

TESTS	RESULTS	FLAG	UNITS	REFERENCE INTERVAL	LAB
Basos	1		%	Not Estab.	01
Immature Cells					01
Neutrophils (Absolute)	3.8		x10E3/uL	1.4-7.0	01
Lymphs (Absolute)	1.8		x10E3/uL	0.7-3.1	01
Monocytes(Absolute)	0.5		x10E3/uL	0.1-0.9	01
Eos (Absolute)	0.4		x10E3/uL	0.0-0.4	01
Baso (Absolute)	0.1		x10E3/uL	0.0-0.2	01
Immature Granulocytes	0		%	Not Estab.	01
Immature Grans (Abs)	0.0		x10E3/uL	0.0-0.1	01
NRBC	Canceled				01
Hematology Comments:					01
Comp. Metabolic Panel (14)					
Glucose	88		mg/dL	65-99	01
BUN	9		mg/dL	6-20	01
Creatinine	0.76		mg/dL	0.57-1.00	01
eGFR If NonAfricn Am	105		mL/min/1.73	>59	01
eGFR If Africn Am	121		mL/min/1.73	>59	01
Labcorp currently reports eGFR in compliance with the current recommendations of the National Kidney Foundation. Labcorp will update reporting as new guidelines are published from the NKF-ASN Task force.					
BUN/Creatinine Ratio	12			9-23	01
Sodium	136		mmol/L	134-144	01
Potassium	4.4		mmol/L	3.5-5.2	01
Chloride	103		mmol/L	96-106	01
Carbon Dioxide, Total	24		mmol/L	20-29	01
Calcium	9.1		mg/dL	8.7-10.2	01
Protein, Total	6.8		g/dL	6.0-8.5	01
Albumin	4.3		g/dL	3.8-4.8	01
Globulin, Total	2.5		g/dL	1.5-4.5	01
A/G Ratio	1.7			1.2-2.2	01

TESTS	RESULTS	FLAG	UNITS	REFERENCE INTERVAL	LAB
Bilirubin, Total	0.3		mg/dL	0.0-1.2	01
Alkaline Phosphatase	56		IU/L	48-121	01
Please note reference interval change					
AST (SGOT)	16		IU/L	0-40	01
ALT (SGPT)	15		IU/L	0-32	01
Lipid Panel					
Cholesterol, Total	161		mg/dL	100-199	01
Triglycerides	58		mg/dL	0-149	01
HDL Cholesterol	50		mg/dL	>39	01
VLDL Cholesterol Cal	12		mg/dL	5-40	01
LDL Chol Calc (NIH)	99		mg/dL	0-99	01
Comment:	Canceled				01
ANA					
Antinuclear Antibodies, IFA	Positive	Abnormal			02
Negative <1:80 Borderline 1:80 Positive >1:80					
Please Note:					02
ANA Multiplex methodology was designed to detect up to 11 antibodies of the 100+ antibodies that may be detected by ANA IFA methodology.					
ENA+DNA/DS+Antich+Centro+FA...					
Homogeneous Pattern	Canceled				02
Nucleolar Pattern	1:160	High			02
Speckled Pattern	Canceled				02
Centromere Pattern	Canceled				02
Spindle Apparatus Pattern	Canceled				02
Nuclear Membrane Pattern	Canceled				02
Midbody Pattern	Canceled				02
Nuclear Dot Pattern	Canceled				02

TESTS	RESULTS	FLAG	UNITS	REFERENCE INTERVAL	LAB
PCNA Pattern	Canceled				02
Centriole Pattern	Canceled				02
Note:					02
<p>A positive ANA result may occur in healthy individuals (low titer) or be associated with a variety of diseases. See interpretation chart which is not all inclusive:</p> <p>Pattern Antigen Detected Suggested Disease Association</p> <p>-----</p> <p>Homogeneous DNA(ds,ss), SLE - High titers Nucleosomes, Histones Drug-induced SLE</p> <p>-----</p> <p>Speckled Sm, RNP, SCL-70, SLE,MCTD,PSS (diffuse form), SS-A/SS-B Sjogrens</p> <p>-----</p> <p>Nucleolar SCL-70, PM-1/SCL High titers Scleroderma, PM/DM</p> <p>-----</p> <p>Centromere Centromere PSS (limited form) w/Crest syndrome variable</p> <p>-----</p> <p>Nuclear Dot Sp100,p80-coilin Primary Biliary Cirrhosis</p> <p>-----</p> <p>Nuclear GP210, Primary Biliary Cirrhosis Membrane lamin A,B,C</p> <p>-----</p>					
Anti-DNA (DS) Ab Qn	11	High	IU/mL	0-9	01
<p>Negative <5 Equivocal 5 - 9 Positive >9</p>					
RNP Antibodies	<0.2		AI	0.0-0.9	01
Smith Antibodies	<0.2		AI	0.0-0.9	01
Antiscleroderma- 70 Antibodies	<0.2		AI	0.0-0.9	01
Sjogren's Anti-SS- A	<0.2		AI	0.0-0.9	01
Sjogren's Anti-SS- B	<0.2		AI	0.0-0.9	01
Antichromatin Antibodies	<0.2		AI	0.0-0.9	01
Anti-Jo-1	<0.2		AI	0.0-0.9	01
Anti-Centromere B Antibodies	<0.2		AI	0.0-0.9	01
See below:					01

TESTS	RESULTS	FLAG	UNITS	REFERENCE INTERVAL	LAB
<div> <div>Autoantibody</div> <div>Disease Association</div> <div>-----</div> <div> <div>Condition</div> <div>Frequency</div> <div>-----</div> </div> <div>Antinuclear Antibody, SLE, mixed connective Direct (ANA-D) tissue diseases</div> <div>-----</div> <div> <div>dsDNA</div> <div>SLE</div> <div>40 - 60%</div> </div> <div>-----</div> <div> <div>Chromatin</div> <div>Drug induced SLE</div> <div>90%</div> </div> <div> <div>SLE</div> <div>48 - 97%</div> </div> <div>-----</div> <div> <div>SSA (Ro)</div> <div>SLE</div> <div>25 - 35%</div> </div> <div> <div>Sjogren's Syndrome</div> <div>40 - 70%</div> </div> <div> <div>Neonatal Lupus</div> <div>100%</div> </div> <div>-----</div> <div> <div>SSB (La)</div> <div>SLE</div> <div>10%</div> </div> <div> <div>Sjogren's Syndrome</div> <div>30%</div> </div> <div>-----</div> <div> <div>Sm (anti-Smith)</div> <div>SLE</div> <div>15 - 30%</div> </div> <div>-----</div> <div> <div>RNP</div> <div>Mixed Connective Tissue Disease</div> <div>95%</div> </div> <div> <div>(U1 nRNP, SLE</div> <div>30 - 50%</div> </div> <div> <div>anti-ribonucleoprotein) Polymyositis and/or Dermatomyositis</div> <div>20%</div> </div> <div>-----</div> <div> <div>Scl-70 (antiDNA topoisomerase)</div> <div>Scleroderma (diffuse)</div> <div>20 - 35%</div> </div> <div> <div>Crest</div> <div>13%</div> </div> <div>-----</div> <div> <div>Jo-1</div> <div>Polymyositis and/or Dermatomyositis</div> <div>20 - 40%</div> </div> <div>-----</div> <div> <div>Centromere B</div> <div>Scleroderma - Crest variant</div> <div>80%</div> </div> </div>					
Hemoglobin A1c					
Hemoglobin A1c	5.1		%	4.8-5.6	01
Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0					
Thyroxine (T4) Free, Direct, S					
T4,Free(Direct)	1.14		ng/dL	0.82-1.77	01
TSH					
TSH	2.000		uIU/mL	0.450-4.500	01
Vitamin D, 25-Hydroxy					
Vitamin D, 25-Hydroxy	27.4	Low	ng/mL	30.0-100.0	01

TESTS	RESULTS	FLAG	UNITS	REFERENCE INTERVAL	LAB
Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30.					
CCP Antibodies IgG/IgA					
CCP Antibodies IgG/IgA	7		units	0-19	03
Negative <20 Weak positive 20 - 39 Moderate positive 40 - 59 Strong positive >59					
Rheumatoid Arthritis Factor					
RA Latex Turbid.	<10.0		IU/mL	0.0-13.9	01
Sedimentation Rate-Westergren					
Sedimentation Rate-Westergren	13		mm/hr	0-32	01
Triiodothyronine (T3), Free					
Triiodothyronine (T3), Free	2.4		pg/mL	2.0-4.4	01
C-Reactive Protein, Quant					
C-Reactive Protein, Quant	<1		mg/L	0-10	01

01	01	LabCorp San Diego 13112 Evening Creek Dr So Ste 200, San Diego, CA 92128-4108	Dir: JennyGallowayMD
02	02	LabCorp Phoenix 5005 S 40th Street Ste 1200, Phoenix, AZ 85040-2969	Dir: EarleCollumMD
03	03	LabCorp Burlington 1447 York Court, Burlington, NC 27215-3361	Dir: SanjaiNagendraMD

For inquiries, the physician may contact Labcorp at 800-222-7566 Lab: 858-668-3700